




RealRate

PHARMACEUTICAL 2016

Lixte Biotechnology Holdings INC
Rank 289 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 6.2% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Assets, reducing the Economic Capital Ratio by 170% points.

The company's Economic Capital Ratio, given in the ranking table, is 20%, being 243% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	598
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	286
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	206
Other Liabilities	0
Other Net Income	200
Other Revenues	0
Property and Equipment	0
Research and Development	2,092
Selling, General and Administrative Expense	754

Output Variable	Value in 1000 USD
Assets	598
Liabilities	286
Expenses	3,052
Revenues	0
Stockholders Equity	312
Net Income	-2,852
Comprehensive Net Income	-2,852
BaseVar	2,068
ECR before LimitedLiability	-491%
Economic Capital Ratio	20%